phrykt

Arcutis Biotherapeutics, Inc. (ARQT): who owns it and who trades it

As of Nov 16, 2026, ARQT insiders reported 68 open-market sales worth $13.9M and no purchases in the last 12 months, with 80% of the sale value made under pre-set 10b5-1 plans. The largest seller was Masaru Matsuda (See Remarks), with $3.4M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Arcutis Biotherapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ARQT

273 funds and institutions reported ARQT shares worth $3.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 9.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Montanova Capital, LLC9.9%
BlackRock, Inc.8.4%
Frazier Life Sciences Management, L.P.7.9%
Rubric Capital Management LP6.6%
Polar Capital Holdings Plc5.3%
State Street Corp4.7%
Vanguard Capital Management LLC4.0%
Morgan Stanley3.6%
Jennison Associates LLC3.4%
D. E. Shaw & Co., Inc.3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC12.44M9.94%$326M+1%
BlackRock, Inc.10.55M8.43%$277M+15%
Frazier Life Sciences Management, L.P.9.87M7.89%$259MNo change
Rubric Capital Management LP8.27M6.61%$217MNo change
Polar Capital Holdings Plc6.61M5.28%$173M+17%
State Street Corp5.82M4.66%$153M-8%
Vanguard Capital Management LLC4.99M3.99%$131M+2%
Morgan Stanley4.45M3.56%$117M+6%
Jennison Associates LLC4.22M3.37%$111M-15%
D. E. Shaw & Co., Inc.3.95M3.16%$104M+58%
UBS Group AG3.33M2.66%$87.4M+0%
California State Teachers Retirement System3.31M2.65%$126M+2480%
Bank of America Corp2.99M2.39%$78.3M+34%
Geode Capital Management, LLC2.98M2.38%$78.2M-2%
Vanguard Portfolio Management LLC2.43M1.94%$63.7M+24%
Orbimed Advisors LLC2.04M1.63%$53.5M–
Franklin Resources Inc1.93M1.54%$50.6M-16%
American Century Companies Inc1.93M1.54%$50.5M+32%
Goldman Sachs Group Inc1.67M1.33%$43.7M+4%
Jupiter Topco LLC1.41M1.13%$37M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ARQT insiders reported $0 of open-market purchases and $13.9M of sales. 80% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$13.9M
68 trades, 10 people
Sales under a 10b5-1 plan
80%
Share of sale value
Latest trade
Nov 4, 2026
Filed Nov 4, 2026

Purchases and sales by month

$2.7M$2.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 4, 2026Masaru MatsudaVice presidentSale plan40,000$34.32$1.4MForm 4
Nov 2, 2026Todd WatanabeDirectorSale4,377$31.86$139KForm 4
Nov 2, 2026Patrick BurnettVice presidentSale943$31.86$30KForm 4
Nov 2, 2026Masaru MatsudaVice presidentSale plan1,219$31.86$38.8KForm 4
Oct 15, 2026Howard G. WelgusDirectorSale plan4,728$26.93$127KForm 4
Sep 16, 2026Masaru MatsudaSee RemarksSale plan3,674$25.00$91.8KForm 4
Sep 15, 2026Howard G. WelgusDirectorSale plan4,730$24.18$114KForm 4
Sep 8, 2026Masaru MatsudaSee RemarksSale plan9,989$25.03$250KForm 4
Aug 27, 2026Terrie CurranDirectorSale11,148$25.03$279KForm 4
Aug 27, 2026Terrie CurranDirectorSale27,052$25.03$677KForm 4
Aug 20, 2026Terrie CurranDirectorSale1,072$26.04$27.9KForm 4
Aug 19, 2026Patrick BurnettSee RemarksSale1,697$27.00$45.8KForm 4
Aug 17, 2026Howard G. WelgusDirectorSale plan4,730$26.18$124KForm 4
Aug 12, 2026Patrick BurnettSee RemarksSale6,700$26.08$175KForm 4
Aug 11, 2026Patrick BurnettSee RemarksSale8,300$26.52$220KForm 4
Aug 3, 2026Patrick BurnettSee RemarksSale plan955$26.12$24.9KForm 4
Aug 3, 2026Masaru MatsudaSee RemarksSale plan1,230$26.12$32.1KForm 4
Aug 3, 2026Todd WatanabeDirectorSale plan4,375$26.12$114KForm 4
Jul 15, 2026Howard G. WelgusDirectorSale plan4,730$26.91$127KForm 4
Jun 17, 2026Howard G. WelgusDirectorSale plan635$25.67$16.3KForm 4
Jun 15, 2026Sue-Jean LinDirectorSale plan4,946$24.38$121KForm 4
Jun 15, 2026Howard G. WelgusDirectorSale plan4,096$24.41$100KForm 4
May 11, 2026Latha VairavanCFOSale plan435$21.05$9.2KForm 4
May 11, 2026Patrick BurnettSee RemarksSale plan222$21.05$4.7KForm 4
May 4, 2026Masaru MatsudaSee RemarksSale plan7,372$23.27$172KForm 4
May 4, 2026Masaru MatsudaSee RemarksSale plan884$23.61$20.9KForm 4
May 4, 2026Patrick BurnettSee RemarksSale plan684$23.61$16.1KForm 4
May 4, 2026Latha VairavanCFOSale plan1,341$23.61$31.7KForm 4
May 4, 2026Todd WatanabeDirectorSale plan3,172$23.61$74.9KForm 4
May 1, 2026Howard G. WelgusDirectorSale plan7,144$22.99$164KForm 4
Apr 1, 2026Howard G. WelgusDirectorSale plan10,000$23.88$239KForm 4
Mar 2, 2026Keith R LeonardDirectorSale plan39,272$25.39$997KForm 4
Mar 2, 2026Howard G. WelgusDirectorSale plan10,000$25.65$256KForm 4
Mar 2, 2026Larry Todd EdwardsSee RemarksSale plan3,584$25.16$90.2KForm 4
Mar 2, 2026Larry Todd EdwardsSee RemarksSale plan103$25.91$2.7KForm 4
Mar 2, 2026Todd WatanabeDirectorSale plan1,068$25.91$27.7KForm 4
Mar 2, 2026Todd WatanabeDirectorSale plan36,281$25.16$913KForm 4
Mar 2, 2026Masaru MatsudaSee RemarksSale plan1,987$25.70$51.1KForm 4
Mar 2, 2026Masaru MatsudaSee RemarksSale plan6,553$25.16$165KForm 4
Mar 2, 2026Masaru MatsudaSee RemarksSale plan193$25.91$5KForm 4
Mar 2, 2026Latha VairavanCFOSale plan81$25.91$2.1KForm 4
Mar 2, 2026Latha VairavanCFOSale plan2,772$25.16$69.7KForm 4
Mar 2, 2026Patrick BurnettSee RemarksSale plan6,106$25.16$154KForm 4
Mar 2, 2026Patrick BurnettSee RemarksSale plan181$25.91$4.7KForm 4
Feb 27, 2026Masaru MatsudaSee RemarksSale plan3,325$27.95$92.9KForm 4
Feb 4, 2026Patrick BurnettSee RemarksSale plan9,794$25.81$253KForm 4
Feb 2, 2026Masaru MatsudaSee RemarksSale plan7,983$25.50$204KForm 4
Feb 2, 2026Masaru MatsudaSee RemarksSale plan4,714$25.63$121KForm 4
Feb 2, 2026Masaru MatsudaSee RemarksSale plan19,379$25.24$489KForm 4
Feb 2, 2026Masaru MatsudaSee RemarksSale plan8,562$24.97$214KForm 4
Feb 2, 2026Patrick BurnettSee RemarksSale plan3,675$25.50$93.7KForm 4
Feb 2, 2026Todd WatanabeDirectorSale plan19,833$25.50$506KForm 4
Feb 2, 2026Latha VairavanCFOSale plan1,320$25.50$33.7KForm 4
Feb 2, 2026Howard G. WelgusDirectorSale plan10,000$25.05$250KForm 4
Feb 2, 2026Larry Todd EdwardsSee RemarksSale plan2,052$25.50$52.3KForm 4
Jan 5, 2026Patrick BurnettSee RemarksSale plan2,490$28.98$72.2KForm 4
Jan 2, 2026Howard G. WelgusDirectorSale plan10,000$28.96$290KForm 4
Dec 31, 2025Patrick BurnettSee RemarksSale plan1,156$29.39$34KForm 4
Dec 31, 2025Patrick BurnettSee RemarksSale plan541$28.81$15.6KForm 4
Dec 15, 2025Patrick BurnettSee RemarksSale plan11,500$28.94$333KForm 4
Dec 1, 2025Masaru MatsudaSee RemarksSale plan1,657$30.23$50.1KForm 4
Dec 1, 2025Howard G. WelgusDirectorSale plan10,000$30.21$302KForm 4
Nov 24, 2025Sue-Jean LinDirectorSale25,272$30.78$778KForm 4
Nov 24, 2025Todd WatanabeDirectorSale plan48,945$30.36$1.5MForm 4
Nov 21, 2025Todd WatanabeDirectorSale plan1,055$30.00$31.6KForm 4
Nov 20, 2025Halley E GilbertDirectorSale16,532$27.55$455KForm 4
Nov 19, 2025Masaru MatsudaSee RemarksSale plan989$27.95$27.6KForm 4
Nov 19, 2025Masaru MatsudaSee RemarksSale plan1,561$28.50$44.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Masaru MatsudaSee Remarks–$3.4MNov 4, 2026
Todd WatanabeSee Remarks, Director–$3.3MNov 2, 2026
Howard G. WelgusDirector–$2.1MOct 15, 2026
Patrick BurnettSee Remarks–$1.5MNov 2, 2026
Keith R LeonardDirector–$997KMar 2, 2026
Terrie CurranDirector–$984KAug 27, 2026
Sue-Jean LinDirector–$898KJun 15, 2026
Halley E GilbertDirector–$455KNov 20, 2025
Latha VairavanSVP Chief Financial Officer–$146KMay 11, 2026
Larry Todd EdwardsSee Remarks–$145KMar 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ARQT short interest

High short interest. 14.4% of ARQT shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 3%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 18.16M ARQT shares were sold short, 14.4% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.40M shares, buying them all back would take about 7.6 trading days (days to cover).

Shares short, % of all shares

14.4%May 15Oct 3018.3%

Days to cover

7.6May 15Oct 3011.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202618.16M14.36%-11%2.40M7.6
Oct 15, 202620.49M16.30%-6%2.10M9.8
Sep 30, 202621.69M17.26%+18%4.49M4.8
Sep 15, 202618.46M14.69%+11%2.16M8.5
Aug 31, 202616.56M13.17%+12%1.76M9.4
Aug 14, 202614.72M11.71%+16%1.83M8.0
Jul 31, 202612.69M10.09%-6%1.18M10.7
Jul 15, 202613.56M10.84%-3%1.45M9.3
Jun 30, 202614.02M11.21%-11%2.21M6.3
Jun 15, 202615.82M12.65%-2%1.58M10.0
May 29, 202616.23M12.97%-8%1.92M8.4
May 15, 202617.55M14.03%+4%2.40M7.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ARQT

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 1 sale of ARQT. The latest was a purchase by Gilbert Ray Cisneros, Jr. on May 29, 2026, reported Jun 8, 2026.

Purchases 2Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
May 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJun 8, 2026Report
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Dec 11, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfJan 12, 2026Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Arcutis Biotherapeutics company events

Arcutis Biotherapeutics filed 7 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 28, 2026LeadershipThe Board of Directors of Arcutis Biotherapeutics, Inc. increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of the Board. Filing
  3. Aug 5, 2026LeadershipL. Todd Edwards notified Arcutis Biotherapeutics, Inc. of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026. Filing
  4. Jul 16, 2026LeadershipThe Board of Directors of Arcutis Biotherapeutics, Inc. increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board. Filing
  5. Jun 9, 2026AnnouncementAs part of a regular review of the corporate governance practices of the Company and in an effort to continue to attract and retain qualified members of the Company’s Board of Directors, which includes compensating eligible non-employee directors appropriately for their services, the Compensation… Filing
  6. Feb 25, 2026ResultsReleased financial results. Filing
  7. Dec 8, 2025LeadershipMr. Bhaskar Chaudhuri retired from his positions as a member of the Board of Directors of Arcutis Biotherapeutics, Inc. and chair of the Compensation Committee of the Board. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Arcutis Biotherapeutics financials

Famous investors that hold ARQT

4 of the 50 well-known investors we track reported holding ARQT in their latest 13F filing. The largest position is Ken Griffin's, worth $40.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.53M$40.5M0.0%+32%
Israel Englander · Millennium ManagementQ3 2026919,391$24.3M0.0%+63%
Jim Simons · Renaissance TechnologiesQ3 2026476,099$12.6M0.0%+715%
Paul Tudor Jones · Tudor Investment CorpQ3 202615,357$406K0.0%-88%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ARQT in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G6.1%
Nov 10, 2026STATE STREET CORPORATION13G6.1%
Oct 5, 2026BlackRock, Inc.13G/A14.1%
Oct 5, 2026BlackRock, Inc.13G/A14.1%

Questions about Arcutis Biotherapeutics, Inc. (ARQT) stock

Who owns the most ARQT stock?

The largest reported owner of Arcutis Biotherapeutics, Inc. (ARQT) is Montanova Capital, LLC, with 9.9% of the company. In total, 273 funds and institutions reported holding ARQT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ARQT insiders buying or selling?

In the last 12 months, ARQT insiders reported no open-market purchases and 68 sales worth $13.9M. The latest trade was on Nov 4, 2026. See every trade.

What is the short interest in ARQT?

As of Oct 30, 2026, 18.16M ARQT shares were sold short, 14.4% of the shares outstanding, down 11.4% from the report before. At the average daily volume of 2.40M shares, buying them all back would take about 7.6 trading days (days to cover). See the history.

Have members of Congress traded ARQT?

Yes. 1 member of Congress reported 2 purchases and 1 sale of ARQT since Nov 17, 2024. The latest was reported on Jun 8, 2026. See the trades.

Which famous investors hold ARQT?

4 of the 50 well-known investors we track reported ARQT in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $40.5M. See all holders.

Executive pay

Arcutis Biotherapeutics's chief executive was paid a total of $7.2M for the year ended Dec 31, 2025, up 96% from $3.7M the year before. In the last 12 months, Arcutis Biotherapeutics's executives and directors bought no stock on the open market and sold $14.9M.

Chief executive, total pay$7.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$20.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.